Treatment protocols
All patients included in our study were treated on (CALGB)/Alliance first-line protocols for patients with acute myeloid leukemia (AML), and received cytarabine/daunorubicin-based induction therapy. Per protocol, all patients were to receive at least one induction cycle. For patients with residual leukemia present in a bone marrow (BM) biopsy after one induction cycle, a second cycle of induction was administered. None of the protocols included allogeneic stem cell transplantation in first complete remission (CR). Patients enrolled on the treatment protocols also provided written informed consent to participate in the companion protocols CALGB 20202 (molecular studies in AML), CALGB 8461 (prospective cytogenetic companion), and CALGB 9665 (leukemia tissue bank), which involved collection of pretreatment BM aspirates and blood samples.
Of the 303 enrolled patients, 77 patients were excluded in outcome analyses due to early induction deaths or did not receive cytarabine as consolidation therapy. Two hundred and twenty [100 with t(8;21) and 126 with inv(16)] received treatment and were included in outcome analyses. Details of the therapeutic schemas for the CALGB protocols have been reported previously [1] [2] [3] [4] 
Definition of clinical endpoints
Clinical endpoints were defined according to generally accepted criteria [5] . CR required a BM aspirate with cellularity >20% with maturation of all cell lines, <5% blasts and undetectable Auer rods; in peripheral blood, an absolute neutrophil count of ≥1.5 × 10 9 /L, platelet count of >100 × 10 9 /L, and leukemic blasts absent; and no evidence of extramedullary leukemia, all of which had to persist for ≥4 weeks [5] . Relapse was defined by the presence of ≥5% BM blasts, or circulating leukemic blasts, or the development of extramedullary leukemia. Overall survival (OS) was measured from the date of study entry until the date of death (from any cause); patients alive at last follow-up were censored. Event-free survival (EFS) was measured from the date of study entry until the date of failure to achieve CR, relapse or death. Patients alive and in CR at last follow-up were censored.
